NeuroCME
LECTURECMECNE

Best of MS Forum® IV

Author(s)/Faculty: Patricia K. Coyle, MD, FAAN, FANA; Guy J. Buckle, MD, MPH; Bruce A. Cohen, MD, FAAN, FANA, FACP; Clyde E. Markowitz, MD; Harold J. Moses Jr., MD
Release Date: 2/12/2018Expiration Date: 2/11/2019
Credit Type: CME / CNENumber of Credits: 2
Content Type: LectureProvider:
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. More than 2.3 million people are affected worldwide, with most being diagnosed between the ages of 20 and 50. Approximately two-thirds of those diagnosed are women. Studies indicate genetic factors cause certain individuals to be more susceptible to the disease, but there is no evidence that MS is directly inherited. Management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. However, until recently, guidance for DMT use has lagged behind the approval of new medications. As such, it is difficult for many clinicians to stay abreast of the latest DMT safety and efficacy data, as well as to synthesize this information to appropriately incorporate these agents into clinical practice. In this CME activity, current treatment guidelines, as well as the safety, efficacy, and utilization of current DMTs, will be discussed. In addition, discussions will include treatment of special patient populations, as well as strategies for overall patient wellness, to enhance the clinician’s confidence in treating patients with MS to provide optimal patient care.